ExpreS2ion Biotech Holding AB (EXPRS2) — Cash Flow-to-Debt Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of Skr684.00K could theoretically repay 0% of its total liabilities (Skr29.42 Million) in one year. See EXPRS2 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ExpreS2ion Biotech Holding AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ExpreS2ion Biotech Holding AB across 10 annual periods. Also explore how fast is ExpreS2ion Biotech Holding AB growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ExpreS2ion Biotech Holding AB (2016–2025)
Year-by-year debt coverage analysis for ExpreS2ion Biotech Holding AB. For market capitalisation and broader financial context, see market value of ExpreS2ion Biotech Holding AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | Skr-40.90 Million | Skr29.42 Million | ▼ -64.4% |
| 2024 | -0.85x | Skr-33.93 Million | Skr40.11 Million | ▲ +88.8% |
| 2023 | -7.57x | Skr-100.89 Million | Skr13.33 Million | ▼ -158.6% |
| 2022 | -2.93x | Skr-99.61 Million | Skr34.04 Million | ▲ +25.6% |
| 2021 | -3.93x | Skr-45.65 Million | Skr11.61 Million | ▼ -425.9% |
| 2020 | -0.75x | Skr-18.18 Million | Skr24.31 Million | ▼ -16.6% |
| 2019 | -0.64x | Skr-12.69 Million | Skr19.79 Million | ▲ +37.0% |
| 2018 | -1.02x | Skr-12.88 Million | Skr12.65 Million | ▼ -24.1% |
| 2017 | -0.82x | Skr-8.61 Million | Skr10.50 Million | ▼ -37.1% |
| 2016 | -0.60x | Skr-7.02 Million | Skr11.73 Million | — |